Replimune Presents Late-Breaking Abstract Featuring Data from IGNYTE Clinical Trial of RP1 Combined with Nivolumab in Anti-PD1 Failed Melanoma at the 39th Annual Meeting of the Society for Immunotherapy of Cancer (SITC 2024)
November 09, 2024 13:00 ET | Source: Replimune Group Inc Oral presentation…
BioAge Labs Reports Third Quarter 2024 Financial Results and Provides Business Updates
November 07, 2024 16:30 ET | Source: BioAge Labs, Inc. Initiated Phase…
LandBridge Company LLC Announces Third Quarter Results and Declares Quarterly Cash Dividend
Delivers revenue growth of 60% year-over-year Declared initial quarterly cash dividend of…
